Medical/Pharmaceuticals
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured
- Volpara shareholder meeting to be held on April 12, 2024: Culminating the acquisition journey for Lunit, finalization set for May SEOUL, South Korea, March 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...
2024-03-13 21:00
1767
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech
company pioneering inin vivo gene editing therapies, today announced
participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin
Miyako Kyoto inKyoto, Japan.
TIDES Asia
2024-03-13 20:00
1513
Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform
SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development. Our platform en...
2024-03-13 09:00
1646
AITRICS to Participate in HIMSS USA 2024
- Three consecutive years of participation in HIMSS USA - Showcasing 'VitalCare' which is an AI Solution for Predicting Patient Deterioration. SEOUL, South Korea, March 12, 2024 /PRNewswire/ -- AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology...
2024-03-12 22:50
1730
Datasea to Drive Growth in its Acoustic Business via Product Upgrades and U.S. Market Entry
BEIJING, March 12, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Hi-tech and 5G-AI multimodal communication technology inChina and the U.S., announced today its latest plan for the Company's...
2024-03-12 22:40
3478
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held inSan Diego, USA, from April 5...
2024-03-12 22:00
1879
Zhongchao Inc. Announces Successful Medication Assistance Services for Over 7,000 SLE Patients with Approximately 130,000 Units of Medications
SHANGHAI, March 12, 2024 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin")...
2024-03-12 20:30
3138
Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD
SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...
2024-03-12 20:00
1592
Baird Medical and ExcelFin Acquisition Corp Announce Strategic Update to Business Combination Terms to Reinforce Long-Term Value Creation Opportunity and Alignment with Shareholders
* Baird Medical agreed to subject 30% of its shares to be received in the transaction to an earnout at a$12.50 trading price * Minimum cash condition of $15 million has been waived, cementing certainty and expediency to our transaction close * Upon closing, Baird Medical is expected to trade...
2024-03-12 19:00
2521
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for...
2024-03-12 09:28
2921
Casio to Release Uterocervical Observation Camera in the United States, Australia and New Zealand
FDA Registration Completed in the United States and TGA Approval Obtained in Australia TOKYO, March 11, 2024 /PRNewswire/ -- Casio Computer Co., Ltd. announced today that the DZ-C100 COLPOCAMERA, which is designed for uterocervical observation and photography in gynecological settings, and the C...
2024-03-12 09:00
1484
Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London
SHANGHAI, March 11, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present its next generation ADC platform IDDC™ and the latest study results of multiple novel ADCs (9MW2821, 7MW3711, 9MW2921) developed...
2024-03-11 22:00
1525
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
BOSTON, March 11, 2024 /PRNewswire/ -- Medicilon, a one-stop pharmaceutical preclinical research and developmentCRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times.Over the past 20 year...
2024-03-11 20:30
1588
ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University
OSAKA, Japan, March 11, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. ( Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it entered into a five-year, university-wide strategic research alliance agreement withHarvard University (Cambridge, MA, USA; "Harvard") aiming at v...
2024-03-11 20:00
1492
TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer
* TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab * TU2218 demonstrated a favorable safety and a synergetic effect with immuno-oncology drugs in preclinical studies BOSTON and SEONGNAM, South Korea, March 11, 2024 /PRNewswire/ -- TiumBio Co.,...
2024-03-11 20:00
1438
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of...
2024-03-11 08:10
1710
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that its Phase 2 trial of the highly selective or...
2024-03-08 23:24
1874
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
Highlights * Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64 Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). * In trial participants where standard of care (SOC) imagin...
2024-03-08 22:02
2012
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or ...
2024-03-08 22:00
2005
Wellysis and Artella Solutions Launch Innovative Remote Cardiac Monitoring Service in the US.
SEOUL, South Korea, March 8, 2024 /PRNewswire/ -- Wellysis, a digital
healthcare company spun off from Samsung, has announced the launch of remote
cardiac monitoring service in the US in partnership with Artella Solutions
(ARTELLA).
2024-03-08 22:00
3211
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
